2. Search Result
Search Result
Results for "

acute myelogenous leukemia

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145723
    MAX-40279

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279
  • HY-145723B
    MAX-40279 hemifumarate

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279 hemifumarate
  • HY-145723C
    MAX-40279 hemiadipate

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279 hemiadipate
  • HY-163406
    PDE1-IN-6

    		Phosphatase Apoptosis Cancer
    PDE1-IN-6 (compound 6c) is a selectivity PDE1 inhibitor with the IC50 of 7.5 nM. PDE1-IN-6 significantly inhibits the proliferation and induced cell apoptosis in Acute myelogenous leukemia cells .
    PDE1-IN-6
  • HY-145723A
    MAX-40279 hydrochloride

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 hydrochloride is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279 hydrochloride
  • HY-149031
    DHODH-IN-22

    		Dihydroorotate Dehydrogenase Cancer
    DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .
    DHODH-IN-22
  • HY-112852A
    TL02-59 dihydrochloride

    		Src Apoptosis Cancer
    TL02-59 dihydrochloride is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 dihydrochloride inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 dihydrochloride potently suppresses acute myelogenous leukemia (AML) cell growth .
    TL02-59 dihydrochloride
  • HY-112852
    TL02-59
    4 Publications Verification

    		 Src Apoptosis Cancer
    TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth .
    TL02-59
  • HY-144371
    DHODH-IN-20

    		Dihydroorotate Dehydrogenase DNA/RNA Synthesis Inflammation/Immunology Cancer
    DHODH-IN-20 (Compound 133) is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-20 inhibits tumor growth. DHODH-IN-20 has the potential for the research of acute myelogenous leukemia .
    DHODH-IN-20
  • HY-10202
    Tandutinib
    5 Publications Verification

    MLN518; CT53518

    		 FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
    Tandutinib
  • HY-10202A
    Tandutinib hydrochloride
    5 Publications Verification

    MLN518 hydrochloride; CT53518 hydrochloride

    		 FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
    Tandutinib hydrochloride
  • HY-50671
    Zosuquidar trihydrochloride
    Maximum Cited Publications
    14 Publications Verification

    RS 33295-198 trihydrochloride; LY-335979 trihydrochloride

    		 P-glycoprotein Cancer
    Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .
    Zosuquidar trihydrochloride
  • HY-15255
    Zosuquidar
    Maximum Cited Publications
    14 Publications Verification

    RS 33295-198; LY-335979

    		 P-glycoprotein Cancer
    Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .
    Zosuquidar
  • HY-150725
    ODN 1585

    		IFNAR TNF Receptor Infection Inflammation/Immunology Cancer
    ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .
    ODN 1585
  • HY-128571
    FLT3-IN-4

    		FLT3 Cancer
    FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia .
    FLT3-IN-4
  • HY-148602
    KH-4-43

    		Others Cancer
    KH-4-43 is an inhibitor of E3 CRL4. KH-4-43 inhibits E3 CRL4's core ligase complex and exhibits anticancer activity. KH-4-43 has a binding Kd to E3 ROC1-CUL4A CTD or the highly related ROC1-CUL1 CTD at 83 nM or 9.4 μM, respectively .
    KH-4-43
  • HY-149735
    BET-IN-20

    		Epigenetic Reader Domain Apoptosis Cancer
    BET-IN-20 (compound 10) is an inhibitor of BRD4 BD1 (IC50=1.9 nM) with anticancer activity. BET-IN-20 can promote acute myeloid leukemia (AML) cell apoptosis and arrest the cell cycle in the G0/G1 phase. BET-IN-20 also inhibits c-Myc and CDK6 and enhances PARP cleavage .
    BET-IN-20
  • HY-16445A
    CNDAC

    		Nucleoside Antimetabolite/Analog Drug Metabolite Apoptosis DNA/RNA Synthesis Cancer
    CNDAC is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC induces DNA damage and apoptosis .
    CNDAC
  • HY-16445B
    CNDAC hydrochloride

    		Nucleoside Antimetabolite/Analog Drug Metabolite Apoptosis DNA/RNA Synthesis Cancer
    CNDAC hydrochloride is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC hydrochloride induces DNA damage and apoptosis .
    CNDAC hydrochloride
  • HY-123141
    K00135

    		Pim Cancer
    K00135 is a potent and selective inhibitor of PIM kinases. K00135 inhibits survival and clonogenic growth of acute leukemia cells. K00135 inhibits the phosphorylation of PIM downstream targets .
    K00135
  • HY-120508
    Pivanex

    AN-9; Pivalyloxymethyl butyrate

    		 HDAC Bcr-Abl Apoptosis Inflammation/Immunology Cancer
    Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties .
    Pivanex

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: